

DNMT3A and *IDH* mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

AP Im, AR Sehgal, MP Carroll, BD Smith, A Tefferi, DE Johnson and M Boyiadzis

Leukemia (2015) **29**, 516; doi:10.1038/leu.2014.269

Correction to: *Leukemia* (2014) **28**, 1774–1783; doi:10.1038/leu.2014.124

Since the publication of this article, the authors have identified an error within the following sentence (page 1780):

Finally, Metzeler *et al.*⁹² evaluated 46 elderly patients with AML treated with decitabine with or without the histone deacetylase inhibitor vorinostat, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).

The correct sentence should read:

Finally, Metzeler *et al.*⁹² evaluated 46 elderly patients with AML treated with decitabine with or without the proteasome inhibitor bortezomib, and found a significantly higher CR rate in patients with DNMT3A mutations (75%) versus wild-type DNMT3A (34%).

The authors would like to apologise for any inconvenience this may have caused.